Crossmark

Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease

Crossref DOI link: https://doi.org/10.1016/j.medcle.2019.07.012

Published Print: 2020-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Elosua González, Alfonso

Sanz Segura, Patricia

Oyón Lara, Daniel

López García, Santiago

Arroyo Villarino, Maria Teresa

Alcalá Escriche, Maria José

Ollero Domenche, Leticia

Rodríguez Gutiérrez, Cristina

Nantes Castillejo, Óscar
License Information

Text and Data Mining valid from 2020-06-01
More Information

This article is maintained by: Elsevier

Article Title: Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease

Journal Title: Medicina Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcle.2019.07.012

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.medcli.2019.07.025

Content Type: article

Copyright: © 2019 Elsevier España, S.L.U. All rights reserved.